secures €38 million to advance its microsurgical robot, MUSA-3
Summary
Revealing MUSA-3, designed to revolutionize the field of micro-surgery Microsures MUSA-3 represent a transformative leap for our field, Prof Neligan, prominent microsurgery expert, author of the standard handbook on Plastic Surgery Clinical studies in preparation for FDA clearance in the US and CE-mark in EuropeEindhoven, The Netherlands, 4 October 2023 Microsure, innovation leader in robot-assisted micro- surgery, announced today the successful closing of its Series B2 investment round securing 38 million in development capital. As part of this financing round, Kreske Nickelsen from new investor kineo will join the supervisory board, further strengthening Microsures governance.Microsures groundbreaking microsurgical robot MUSA-3 is designed to revolutionize the field of open microsurgery, helping microsurgeons to excel and to leave no patient untreated. It represents a monumental leap in microsurgical technology, poised to empower surgeons with unprecedented precision, stability and control beyond human capabilities, elevating patient care to new heights in the future of microsurgery. These studies, performed at Maastricht University Medical Center in the Netherlands and Uppsala Academic Hospital in Sweden include about 50 patients to date and encompass a wide spectrum of surgical indications, yielding promising results and invaluable insights for the development of MUSA-3. The financing will enable us to advance our groundbreaking technology and bring innovative solutions to patients worldwide through our MUSA-3 robotic system.The tireless efforts of the Microsure team over the past years have culminated in the development of a truly unique robot celebrated for its precision, ergonomic design, and adaptability for a wide spectrum of intricate procedures.Our progress is a testament to the exceptional talent within our growing team of dedicated individuals, and the seamless collaboration with our key development and manufacturing partners.